Moxidectin Sponsors Credit PRV Program For Enabling River Blindness Approval
Medicines Development for Global Health is the first nonprofit to earn a priority review voucher for bringing a neglected tropical disease therapy to US approval. Project carried on research from the Wyeth era.
You may also be interested in...
Novartis’ Attention To Tropical Diseases Pays Off: Liver Fluke Drug Egaten Earns Priority Review Voucher
US FDA approval expected to facilitate global use of one-day oral treatment of fascioliasis, a designated neglected tropical disease, which Novartis developed with the World Health Organization.
With at least 40 pending novel products, FDA seems poised to break its 2017 approval record of 46, and could even reach 60.
Only the first publicly disclosed sale of a priority review voucher was lower than what Jazz Pharmaceuticals paid Spark Therapeutics for its coupon.